Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Study sponsor: Actinium Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-06Actual
Enrollment · participants153Actual
Source updated2023-07-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.